FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972371407> ?p ?o ?g. }

• W1972371407 endingPage "e654" @default.
• W1972371407 startingPage "e647" @default.
• W1972371407 abstract "Purpose To evaluate outcomes of patients treated for aggressive non-Hodgkin lymphoma (NHL) with combined modality therapy based on [18F]fluoro-2-deoxy-2-d-glucose positron emission tomography (FDG-PET) response. Methods and Materials We studied 59 patients with aggressive NHL, who received chemotherapy and radiation therapy (RT) from 2001 to 2008. Among them, 83% of patients had stage I/II disease. Patients with B-cell lymphoma received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-based chemotherapy, and 1 patient with anaplastic lymphoma kinase-negative anaplastic T-cell lymphoma received CHOP therapy. Interim and postchemotherapy FDG-PET or FDG-PET/computed tomography (CT) scans were performed for restaging. All patients received consolidated involved-field RT. Median RT dose was 36 Gy (range, 28.8-50 Gy). Progression-free survival (PFS) and local control (LC) rates were calculated with and without a negative interim or postchemotherapy FDG-PET scan. Results Median follow-up was 46.5 months. Thirty-nine patients had negative FDG-PET results by the end of chemotherapy, including 12 patients who had a negative interim FDG-PET scan and no postchemotherapy PET. Twenty patients were FDG-PET-positive, including 7 patients with positive interim FDG-PET and no postchemotherapy FDG-PET scans. The 3-year actuarial PFS rates for patients with negative versus positive FDG-PET scans were 97% and 90%, respectively. The 3-year actuarial LC rates for patients with negative versus positive FDG-PET scans were 100% and 90%, respectively. Conclusions Patients who had a positive interim or postchemotherapy FDG-PET had a PFS rate of 90% at 3 years after combined modality treatment, suggesting that a large proportion of these patients can be cured with consolidated RT. To evaluate outcomes of patients treated for aggressive non-Hodgkin lymphoma (NHL) with combined modality therapy based on [18F]fluoro-2-deoxy-2-d-glucose positron emission tomography (FDG-PET) response. We studied 59 patients with aggressive NHL, who received chemotherapy and radiation therapy (RT) from 2001 to 2008. Among them, 83% of patients had stage I/II disease. Patients with B-cell lymphoma received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-based chemotherapy, and 1 patient with anaplastic lymphoma kinase-negative anaplastic T-cell lymphoma received CHOP therapy. Interim and postchemotherapy FDG-PET or FDG-PET/computed tomography (CT) scans were performed for restaging. All patients received consolidated involved-field RT. Median RT dose was 36 Gy (range, 28.8-50 Gy). Progression-free survival (PFS) and local control (LC) rates were calculated with and without a negative interim or postchemotherapy FDG-PET scan. Median follow-up was 46.5 months. Thirty-nine patients had negative FDG-PET results by the end of chemotherapy, including 12 patients who had a negative interim FDG-PET scan and no postchemotherapy PET. Twenty patients were FDG-PET-positive, including 7 patients with positive interim FDG-PET and no postchemotherapy FDG-PET scans. The 3-year actuarial PFS rates for patients with negative versus positive FDG-PET scans were 97% and 90%, respectively. The 3-year actuarial LC rates for patients with negative versus positive FDG-PET scans were 100% and 90%, respectively. Patients who had a positive interim or postchemotherapy FDG-PET had a PFS rate of 90% at 3 years after combined modality treatment, suggesting that a large proportion of these patients can be cured with consolidated RT." @default.
• W1972371407 created "2016-06-24" @default.
• W1972371407 creator A5005866115 @default.
• W1972371407 creator A5022220719 @default.
• W1972371407 creator A5058888805 @default.
• W1972371407 creator A5069129452 @default.
• W1972371407 creator A5073778143 @default.
• W1972371407 creator A5077388635 @default.
• W1972371407 creator A5085801543 @default.
• W1972371407 date "2012-08-01" @default.
• W1972371407 modified "2023-10-01" @default.
• W1972371407 title "Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma: Favorable Outcomes of Combined Modality Treatment for Patients With Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET" @default.
• W1972371407 cites W1972151064 @default.
• W1972371407 cites W1989826112 @default.
• W1972371407 cites W1990827442 @default.
• W1972371407 cites W2032697065 @default.
• W1972371407 cites W2035578984 @default.
• W1972371407 cites W2037797717 @default.
• W1972371407 cites W2058255870 @default.
• W1972371407 cites W2084082379 @default.
• W1972371407 cites W2085413477 @default.
• W1972371407 cites W2097134772 @default.
• W1972371407 cites W2101395460 @default.
• W1972371407 cites W2122863546 @default.
• W1972371407 cites W2128563268 @default.
• W1972371407 cites W2130929003 @default.
• W1972371407 cites W2133201432 @default.
• W1972371407 cites W2135432883 @default.
• W1972371407 cites W2142724147 @default.
• W1972371407 cites W2144795394 @default.
• W1972371407 cites W2152345349 @default.
• W1972371407 cites W2161205944 @default.
• W1972371407 cites W2165459402 @default.
• W1972371407 cites W2166337528 @default.
• W1972371407 cites W2171493516 @default.
• W1972371407 cites W254931162 @default.
• W1972371407 cites W2558496034 @default.
• W1972371407 cites W2584445014 @default.
• W1972371407 cites W4205736005 @default.
• W1972371407 doi "https://doi.org/10.1016/j.ijrobp.2012.01.060" @default.
• W1972371407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22607911" @default.
• W1972371407 hasPublicationYear "2012" @default.
• W1972371407 type Work @default.
• W1972371407 sameAs 1972371407 @default.
• W1972371407 citedByCount "19" @default.
• W1972371407 countsByYear W19723714072012 @default.
• W1972371407 countsByYear W19723714072013 @default.
• W1972371407 countsByYear W19723714072014 @default.
• W1972371407 countsByYear W19723714072015 @default.
• W1972371407 countsByYear W19723714072016 @default.
• W1972371407 countsByYear W19723714072018 @default.
• W1972371407 countsByYear W19723714072019 @default.
• W1972371407 countsByYear W19723714072021 @default.
• W1972371407 crossrefType "journal-article" @default.
• W1972371407 hasAuthorship W1972371407A5005866115 @default.
• W1972371407 hasAuthorship W1972371407A5022220719 @default.
• W1972371407 hasAuthorship W1972371407A5058888805 @default.
• W1972371407 hasAuthorship W1972371407A5069129452 @default.
• W1972371407 hasAuthorship W1972371407A5073778143 @default.
• W1972371407 hasAuthorship W1972371407A5077388635 @default.
• W1972371407 hasAuthorship W1972371407A5085801543 @default.
• W1972371407 hasConcept C126322002 @default.
• W1972371407 hasConcept C126838900 @default.
• W1972371407 hasConcept C2775842073 @default.
• W1972371407 hasConcept C2776694085 @default.
• W1972371407 hasConcept C2776755627 @default.
• W1972371407 hasConcept C2779338263 @default.
• W1972371407 hasConcept C2779429289 @default.
• W1972371407 hasConcept C2779725641 @default.
• W1972371407 hasConcept C2989005 @default.
• W1972371407 hasConcept C71924100 @default.
• W1972371407 hasConceptScore W1972371407C126322002 @default.
• W1972371407 hasConceptScore W1972371407C126838900 @default.
• W1972371407 hasConceptScore W1972371407C2775842073 @default.
• W1972371407 hasConceptScore W1972371407C2776694085 @default.
• W1972371407 hasConceptScore W1972371407C2776755627 @default.
• W1972371407 hasConceptScore W1972371407C2779338263 @default.
• W1972371407 hasConceptScore W1972371407C2779429289 @default.
• W1972371407 hasConceptScore W1972371407C2779725641 @default.
• W1972371407 hasConceptScore W1972371407C2989005 @default.
• W1972371407 hasConceptScore W1972371407C71924100 @default.
• W1972371407 hasIssue "5" @default.
• W1972371407 hasLocation W19723714071 @default.
• W1972371407 hasLocation W19723714072 @default.
• W1972371407 hasOpenAccess W1972371407 @default.
• W1972371407 hasPrimaryLocation W19723714071 @default.
• W1972371407 hasRelatedWork W115168992 @default.
• W1972371407 hasRelatedWork W1973158710 @default.
• W1972371407 hasRelatedWork W1998397384 @default.
• W1972371407 hasRelatedWork W1999202698 @default.
• W1972371407 hasRelatedWork W2017047848 @default.
• W1972371407 hasRelatedWork W2060816095 @default.
• W1972371407 hasRelatedWork W2093020189 @default.
• W1972371407 hasRelatedWork W2343777302 @default.
• W1972371407 hasRelatedWork W2467938374 @default.
• W1972371407 hasRelatedWork W3139536412 @default.
• W1972371407 hasVolume "83" @default.
• W1972371407 isParatext "false" @default.

• next